Antibody binding to native cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans
Vaccine protection profile Cytomegalovirus (CMV) is a leading cause of posttransplant complications and congenital infections, but there are no CMV vaccines currently licensed. Jenks et al. characterized